KEYNOTE-407: Practice-Changing Positive Trial for Advanced Squamous NSCLC (BMIC-039)
Jun 20, 2018•10 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Dr. Jack West reviews KEYNOTE-407, first line chemo/immunotherapy with pembrolizumab vs. chemo alone in advanced squamous NSCLC, which demonstrated a significant survival benefit that should change practice in this setting.
For the best experience, listen in Metacast app for iOS or Android
Open in Metacast